

February 5, 2019

Whom It May Concern

Company: KYORIN Holdings, Inc.  
Representative: Minoru Hogawa  
Representative Director, President  
(Security Code: 4569, TSE 1st Sec.)  
Contact: Shuji Miyaki  
Director, Corporate Communication  
President Office  
Telephone: (0)3-3525-4707

## The Revision of Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019

KYORIN Holdings, Inc. (the “Company”) today announced that, at a meeting of the Board of Directors held on February 5, 2019, the Company made the following revisions to the consolidated earnings forecasts for the fiscal year ending March 31, 2019 disclosed (at the time of the financial results announcement) on May 10, 2018.

### 1. The Revision of Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019

	Net sales	Operating income	Ordinary income	Net income	Basic earnings per share
	Million Yen	Million Yen	Million Yen	Million Yen	Yen
Original forecast (A)	114,400	8,600	9,200	6,600	100.68
<b>Revised forecast (B)</b>	<b>110,600</b>	<b>8,200</b>	<b>8,600</b>	<b>6,100</b>	<b>92.96</b>
Change (B-A)	-3,800	-400	-600	-500	—
Change (%)	-3.3	-4.7	-6.5	-7.6	—
(for reference) Results of the previous period	110,640	8,822	9,345	6,574	89.28

### 2. Reason for revision of consolidated financial forecast

The Company revised its financial forecast in light of business results for the first nine months of the current fiscal year and the voluntary recall of DESALEX Tablets 5mg for the treatment of allergic diseases (see the news release dated January 7, 2019 for further details).

#### [Net sales]

For the reason stated above, in the ethical drugs business, revenues from core products such as PENTASA and DESALEX are now expected to be less than forecast.

#### [Profits]

The Company revised its profit forecasts as shown in the above table as it expects that gross profit will decrease due to the downward revision of sales but that SG&A expenses will be less than initially forecast thanks to cost-cutting initiatives implemented since the beginning of the current fiscal year.

The Company is currently consulting MSD K.K., which is the holder of marketing approval for DESALAX, regarding action to be taken in response to the voluntary recall and suspension of sales for DESALEX, and will promptly disclose any new information that requires disclosure.

(Note) The above forecasts are based on information that is currently available and actual results may differ materially from those in the forecasts.